Bayer (FRA:BAYN) has been given a €81.00 ($94.19) target price by equities researchers at Independent Research in a research report issued to clients and investors on Tuesday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the healthcare company’s stock. Independent Research’s target price indicates a potential upside of 6.96% from the company’s previous close.
Several other equities research analysts have also weighed in on BAYN. Kepler Capital Markets set a €73.00 ($84.88) target price on shares of Bayer and gave the stock a “neutral” rating in a report on Thursday, January 9th. Goldman Sachs Group set a €77.00 ($89.53) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Monday, November 18th. Warburg Research set a €61.00 ($70.93) target price on shares of Bayer and gave the stock a “neutral” rating in a research note on Friday. Baader Bank set a €123.00 ($143.02) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Monday. Finally, UBS Group set a €110.00 ($127.91) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Tuesday, November 19th. Eight research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of €81.12 ($94.32).
Shares of BAYN opened at €75.73 ($88.06) on Tuesday. The company has a 50-day simple moving average of €72.24 and a 200-day simple moving average of €66.52. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.